Atopic dermatitis
Methodology & AI Transparency ⓘ
Atopic dermatitis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Atopic dermatitis—coded clinically as L20.9 across Skin & Dermatology guidelines—combines topical retinoids/calcineurin/steroid sparing in Atopic dermatitis (L20.9: regimens) with structured follow-up of 25-Hydroxy Vitamin D in Atopic dermatitis (L20.9: & hs-CRP) (25(OH)D 40–65 ng/mL (L20.9)).
- 2 Real-world patient consensus: Clinical coding for Atopic dermatitis uses ICD-10 L20.9 across Skin & Dermatology specialty care.
- 3 Typical cash cost range: Differential triage of Atopic dermatitis (L20.9) utilizes topical retinoids/calcineurin/steroid sparing in Atopic dermatitis (L20.9: regimens).
- 4 Top reported side effects / signs: Follow-up benchmark in Atopic dermatitis: maintaining Fasting Lipids & in Atopic dermatitis (L20.9: ALT (if systemic) within Within baseline reference limits (L20.9).
Ask our AI Specialists anything about Atopic dermatitis
What Is Atopic dermatitis?
Atopic dermatitis—coded clinically as L20.9 across Skin & Dermatology guidelines—combines topical retinoids/calcineurin/steroid sparing in Atopic dermatitis (L20.9: regimens) with structured follow-up of 25-Hydroxy Vitamin D in Atopic dermatitis (L20.9: & hs-CRP) (25(OH)D 40–65 ng/mL (L20.9)).
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Atopic dermatitis (L20.9) features cutaneous immune skewing in Atopic dermatitis (L20.9: (Th2/IL-4/IL-13 in atopic). therapeutic stabilization in skin & dermatology is verified against 25-Hydroxy Vitamin D in Atopic dermatitis (L20.9: & hs-CRP).
Common Symptoms & Clinical Signs
- • Presentation of Atopic dermatitis (L20.9): recurrent flares triggered in Atopic dermatitis (L20.9: by UV exposure,)
- • Secondary Atopic dermatitis clinical sign: persistent erythematous plaques, in Atopic dermatitis (L20.9: scaly patches, pruritic)
- • Symptom flares in Atopic dermatitis correlating with Fasting Lipids & in Atopic dermatitis (L20.9: ALT (if systemic) deviation outside Within baseline reference limits (L20.9)
- • Functional skin & dermatology impact requiring topical retinoids/calcineurin/steroid sparing in Atopic dermatitis (L20.9: regimens) evaluation (L20.9)
Atopic dermatitis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L20.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NLM Clinical Tables |
| Diagnostic / Lab Marker: Fasting Lipids & in Atopic dermatitis (L20.9: ALT (if systemic) | Within baseline reference limits (L20.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Atopic dermatitis (L20.9: & hs-CRP) | 25(OH)D 40–65 ng/mL (L20.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Atopic dermatitis (L20.9: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L20.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Atopic dermatitis
Treatment selection for Atopic dermatitis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Atopic dermatitis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe: What a 2,856-Participant Study Found Abrocitinib, with proper patient and dose selection, has a manageable tolerability and longer-term safety profile appropriate for long-term use in patients with moderate-to-severe AD. American journal of clinical dermatology • 2021-09-15 • Phase III Randomized Trial | N = 2,856 | 96/100 | PMID 34406619 ↗ |
| New Insights on Immunogenicity of dupilumab in adult and children patients with: What a 2,992-Participant Study Found In patients with AD, ADAs and NAbs had minimal impact on dupilumab concentration, efficacy, and safety, except for high-titer ADAs in a small number of patients. Frontiers in immunology • 2024-01-15 • Phase III Randomized Trial | N = 2,992 | 96/100 | PMID 39588375 ↗ |
| New Insights on Upadacitinib for moderate-to-severe eczema: Stratified analysis from three: What a 2,584-Participant Study Found Upadacitinib had consistently high skin clearance rates and itch efficacy across subgroups of patients with moderate-to-severe AD through Week 16. Journal of the European Academy of Dermatology and Venereology : JEADV • 2023-09-15 • Phase III Randomized Trial | N = 2,584 | 96/100 | PMID 37247226 ↗ |
| New Insights on Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults: What a 2,444-Participant Study Found In four large phase 3 trials in adults with moderate-to-severe AD, dupilumab treatment with or without concomitant TCS resulted in rapid and sustained improvements in all SCORAD outcomes vs. The Journal of dermatological treatment • 2022-02-15 • Phase III Randomized Trial | N = 2,444 | 96/100 | PMID 32347763 ↗ |
| New Insights on Bilateral Association Between eczema® and hair loss: What a 233,448-Participant Study Found Based on 7 studies, there was a significant association between AD and AA when AA was the exposure factor [odds ratio, OR, = 4.537 (95% CI: 2.409-8.544)]; based on 10 studies, there was also a significant association between... Dermatitis : contact, atopic, occupational, drug • 2024-01-15 • Meta-Analysis | N = 233,448 | 94/100 | PMID 37471232 ↗ |
Atopic dermatitis Patient Community & “People Like Me” Threads
Filter Atopic dermatitis community threads and patient logs by age, biological sex, dosage, and treatment duration.